These results suggested that BSKS could alleviate hepatic steatosis in HF-fed mice, through improving the degree of liver adiponectin resistance, which might be involved in regulating dyslipidemia and inhibiting the inflammatory response via TLR4 and NF-κB p65 signaling pathway. Here, TLR4 is linked to metabolic syndrome.